Seaport Therapeutics is a pre-revenue, clinical-stage biotechnology company that invents and develops oral medicines for depression, anxiety and other neuropsychiatric disorders. Its strategy is to take clinically validated mechanisms with established efficacy and safety that have been limited by high first-pass metabolism, low bioavailability and/or side effects, and use its proprietary Glyph platform to overcome those limitations. Its pipeline includes:
- GlyphAllo (SPT-300, Glyph allopregnanolone), in the potentially registration-enabling Phase 2b BUOY-1 trial for major depressive disorder with or without anxious distress; it recently showed no impairment of next-morning driving in a Phase 1 trial.
- GlyphAgo (SPT-320, Glyph agomelatine), in a Phase 2a trial for generalized anxiety disorder with sleep disturbance, with a Phase 2/3 GAD trial planned for 1H 2027.
- Glyph2BLSD (SPT-348, Glyph 2-bromo-LSD), a preclinical non-hallucinogenic neuroplastogen for neuropsychiatric and headache disorders.
The company is listed on Nasdaq under SPTX and funds operations from its cash and investments. Updated
Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who…
Seaport Therapeutics is a pre-revenue, clinical-stage biotechnology company that invents and develops oral medicines for depression, anxiety and other neuropsychiatric disorders.
